For FY25, the company expects total research and development plus selling, general and administrative expenses to be $380M-$385M, compared to prior guidance of $370M-$390M, both estimates excluding an estimated $45M in non-cash stock compensation expense. Syndax (SNDX) expects that its operating expense base will remain stable over the next few years. As a result, Syndax expects that its cash, cash equivalents and short- and long-term investments, combined with its anticipated product revenue and interest income, will enable the company to reach profitability.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Syndax options imply 10.9% move in share price post-earnings
- Syndax announces Revuforj, Niktimvo data accepted for presentation at ASH 2025
- SNDX Upcoming Earnings Report: What to Expect?
- Syndax Pharmaceuticals Launches Promising Phase 3 AML Study with Revumenib
- Syndax Pharmaceuticals’ Revumenib Study: A Potential Game-Changer in Leukemia Treatment